Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.

Torben BiesterIdo MullerThekla von dem BergeEran AtlasRevital Nimri Moshe Phillip Tadej Battelino Natasa Bratina Klemen DovcMarkus F ScheererOlga Kordonouri Thomas Danne

Published in: Diabetes, obesity & metabolism (2020)

In adolescents and adults with T1D, dapagliflozin significantly increased TIR on average by 259 minutes/day while reducing glycaemic variability during FCL control without any signs of hypoglycaemia or ketosis.

Keyphrases

type diabetes
young adults
physical activity
stem cells
bone marrow
cell therapy